Peter Vanlandschoot

TL;DR: The enhanced immunogenicity of the M2 extracellular domain exposed on HBc particles allows broad-spectrum, long-lasting protection against influenza A infections.

TL;DR: The nanobody platform may be highly effective at generating extremely potent and selective G protein-coupled receptor modulators in response to conventional monoclonal antibodies.

TL;DR: The results show that multimerization of VHH fragments targeting multiple epitopes on a viral trimeric spike protein is a powerful tool for anti-viral therapy to achieve “best-in-class” and broader neutralization capacity.

TL;DR: The described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies, and allow tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity.

TL;DR: Mechanistically, CXCR7-targeting Nanobodies did not inhibit cell cycle progression but instead reduced secretion of the angiogenic chemokine CXCL1 from head and neck cancer cells in vitro, thus acting here as inverse agonists, and subsequent angiogenesis in vivo, further substantiate the therapeutic relevance of targeting CX CR7 in head and head cancer.